サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1786786

抗真菌薬の世界市場、規模、シェア、動向、産業分析レポート：薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別 - 市場予測、2025年～2034年

Antifungal Drugs Market Size, Share, Trend, Industry Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication, By Dosage Form, By Distribution Channel, By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 129 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
抗真菌薬の世界市場、規模、シェア、動向、産業分析レポート：薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別 - 市場予測、2025年～2034年
出版日: 2025年07月01日
発行: Polaris Market Research
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、抗真菌薬市場規模は2034年までに232億2,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

抗真菌薬市場は、皮膚、爪、粘膜、内臓に影響を及ぼす幅広い真菌感染症の治療に使用される医薬品の開発、生産、流通に焦点を当てています。特に、がん治療中や臓器移植中、慢性疾患を患っている免疫不全患者の間で真菌症が増加していることが、効果的な抗真菌療法に対する安定した需要を牽引しています。

院内真菌感染症の増加により、医療プロバイダーは抗真菌薬を予防・治療プロトコールに組み込む必要に迫られています。業界動向は、標的療法、ドラッグデリバリーシステムの改良、耐性や毒性の問題を克服するための新規製剤の使用へのシフトを示しています。局所投与、経口投与、静脈内投与といったデリバリープラットフォームにおける絶え間ない技術革新は、患者のアドヒアランスと治療効果を高めています。製薬会社はまた、耐性株や侵襲性感染を標的とした新世代の抗真菌薬にも投資しています。

診断能力の拡大により早期発見が可能になり、治療成績の向上と処方量の増加に寄与しています。現在、最適な治療法が確立されていない特定の適応症に対する抗真菌薬の開発や、十分な医療サービスが提供されていない新興国市場でのアクセス拡大にも治療機会があります。各社は、再製剤や合剤など、既存薬のライフサイクル管理にますます力を注いでいます。さらに、抗菌薬耐性への対処を目的としたグローバルヘルスイニシアチブは、資金提供やパートナーシップの余地を生み出し、抗真菌薬領域を臨床研究の活発な領域にしています。技術や治療法の進歩に加え、患者の安全性が重視されるようになったことで、抗真菌薬市場は競合と技術革新に牽引される様相を呈しています。

抗真菌薬市場レポートハイライト

薬剤クラス別では、アゾール系薬剤が広域スペクトル活性と表在性・全身性真菌感染症の治療における確立された臨床効果により、2024年の売上シェアの48%を占めました。

適応症別では、カンジダ症が免疫不全患者や入院患者の間で高い有病率を示すことから、2024年に最大の売上シェアを占めました。

2024年には、北米が世界の抗真菌薬市場収益の約41%を占めましたが、これは高度な医療インフラの存在、免疫抑制療法の頻繁な使用、高齢者人口の増加によるものです。

アジア太平洋地域は、医療へのアクセスが急速に改善し、真菌感染症に対する認識が高まっていることから、予測期間中に最も高いCAGRを記録すると予想されます。

世界の主要企業には、Abbott、Astellas Pharma, Inc.、Bayer AG、Enzon Pharmaceuticals, Inc.、Glenmark、GSK plc、Merck & Co., Inc.、Novartis AG、Pfizer, Inc.、Sanofiなどがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 抗真菌薬市場の洞察

  • 市場スナップショット
  • 抗真菌薬市場力学
    • 促進要因と機会
      • 高齢化人口の増加
      • 真菌感染症の蔓延
    • 抑制要因と課題
      • 製品の高コスト
  • PESTEL分析
  • 抗真菌薬市場の力の評価動向
  • バリューチェーン分析

第5章 抗真菌薬市場：薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • アゾール
  • エキノキャンディン
  • ポリエン
  • アリルアミン
  • その他

第6章 抗真菌薬市場：適応症別

  • 主な調査結果
  • イントロダクション
  • 皮膚糸状菌症
  • アスペルギルス症
  • カンジダ症
  • その他

第7章 抗真菌薬市場：剤形別

  • 主な調査結果
  • イントロダクション
  • 経口薬
  • 軟膏
  • 粉末
  • その他

第8章 抗真菌薬市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第9章 抗真菌薬市場：地域別

  • 主な調査結果
  • イントロダクション
    • 抗真菌薬市場分析：地域別、2020～2034年
  • 北米
    • 北米：薬剤クラス別、2020-2034年
    • 北米：適応症別、2020～2034年
    • 北米：流通チャネル別、2020～2034年
    • 北米：剤形別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：薬剤クラス別、2020-2034年
    • 欧州：適応症別、2020～2034年
    • 欧州：流通チャネル別、2020～2034年
    • 欧州：剤形別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋地域
    • アジア太平洋地域：薬剤クラス別、2020年～2034年
    • アジア太平洋地域：適応症別、2020～2034年
    • アジア太平洋地域：流通チャネル別、2020～2034年
    • アジア太平洋地域：剤形別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：薬剤クラス別、2020～2034年
    • 中東・アフリカ：症状別、2020～2034年
    • 中東・アフリカ：流通チャネル別、2020～2034年
    • 中東・アフリカ：剤形別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：薬剤クラス別、2020-2034年
    • ラテンアメリカ：兆候別、2020-2034年
    • ラテンアメリカ：流通チャネル別、2020～2034年
    • ラテンアメリカ：剤形別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第10章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • Abbott
  • Astellas Pharma, Inc.
  • Bayer AG
  • Enzon Pharmaceuticals, Inc.
  • Glenmark
  • GSK plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc
  • Sanofi
図表

List of Tables:

  • Table 1 Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 2 Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 3 Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 4 Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 5 North America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 6 North America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 7 North America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 8 North America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 9 US: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 10 US: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 11 US: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 12 US: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 13 Canada: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 14 Canada: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 15 Canada: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 16 Canada: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 17 Europe: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 18 Europe: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 19 Europe: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 20 Europe: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 21 UK: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 22 UK: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 23 UK: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 24 UK: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 25 France: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 26 France: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 27 France: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 28 France: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 29 Germany: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 30 Germany: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 31 Germany: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 32 Germany: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 33 Italy: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 34 Italy: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 35 Italy: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 36 Italy: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 37 Spain: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 38 Spain: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 39 Spain: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 40 Spain: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 41 Netherlands: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 42 Netherlands: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 43 Netherlands: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 44 Netherlands: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 45 Russia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 46 Russia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 47 Russia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 48 Russia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 49 Rest of Europe: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 50 Rest of Europe: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 51 Rest of Europe: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 52 Rest of Europe: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 53 Asia Pacific: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 54 Asia Pacific: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 55 Asia Pacific: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 56 Asia Pacific: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 57 China: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 58 China: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 59 China: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 60 China: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 61 India: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 62 India: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 63 India: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 64 India: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 65 Malaysia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 66 Malaysia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 67 Malaysia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 68 Malaysia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 69 Japan: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 70 Japan: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 71 Japan: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 72 Japan: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 73 Indonesia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 74 Indonesia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 75 Indonesia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 76 Indonesia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 77 South Korea: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 78 South Korea: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 79 South Korea: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 80 South Korea: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 81 Australia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 82 Australia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 83 Australia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 84 Australia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 85 Rest of Asia Pacific: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 86 Rest of Asia Pacific: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 87 Rest of Asia Pacific: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 88 Rest of Asia Pacific: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 89 Middle East & Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 90 Middle East & Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 91 Middle East & Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 92 Middle East & Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 93 Saudi Arabia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 94 Saudi Arabia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 95 Saudi Arabia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 96 Saudi Arabia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 97 UAE: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 98 UAE: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 99 UAE: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 100 UAE: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 101 Israel: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 102 Israel: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 103 Israel: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 104 Israel: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 105 South Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 106 South Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 107 South Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 108 South Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 109 Rest of Middle East & Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 110 Rest of Middle East & Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 111 Rest of Middle East & Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 112 Rest of Middle East & Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 113 Latin America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 114 Latin America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 115 Latin America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 116 Latin America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 117 Mexico: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 118 Mexico: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 119 Mexico: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 120 Mexico: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 121 Brazil: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 122 Brazil: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 123 Brazil: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 124 Brazil: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 125 Argentina: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 126 Argentina: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 127 Argentina: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 128 Argentina: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • Table 129 Rest of Latin America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
  • Table 130 Rest of Latin America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • Table 131 Rest of Latin America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 132 Rest of Latin America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Antifungal Drugs Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Antifungal Drugs Market, By Drug Class, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Indication
  • Figure 9. Antifungal Drugs Market, By Indication, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Antifungal Drugs Market, by Distribution Channel, 2024 & 2034 (USD Billion)
  • Figure 12. Market by Dosage Form
  • Figure 13. Antifungal Drugs Market, by Dosage Form, 2024 & 2034 (USD Billion)
目次
Product Code: PM6045

The antifungal drugs market size is expected to reach USD 23.22 billion by 2034, according to a new study by Polaris Market Research. The report "Antifungal Drugs Market Size, Share, Trend, Industry Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication, By Dosage Form, By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The antifungal drugs market focuses on the development, production, and distribution of medications used to treat a wide range of fungal infections affecting the skin, nails, mucous membranes, and internal organs. Rising cases of fungal diseases, particularly among immunocompromised individuals undergoing cancer treatments, organ transplantation, or suffering from chronic illnesses, are driving steady demand for effective antifungal therapies.

The increasing incidence of hospital-acquired fungal infections is pushing healthcare providers to incorporate antifungal agents into preventive and treatment protocols. Industry trends indicate a shift toward the use of targeted therapies, improved drug delivery systems, and novel formulations designed to overcome resistance and toxicity issues. Continuous innovation in topical, oral, and intravenous delivery platforms is enhancing patient adherence and treatment efficacy. Pharmaceutical companies are also investing in new-generation antifungal agents that target resistant strains and invasive infections.

Expanding diagnostic capabilities are enabling early detection, which improves outcomes and fuels prescription volumes. Opportunities lie in developing antifungal solutions for specific indications that currently lack optimal treatments, as well as expanding access in underserved healthcare markets. Companies are increasingly focusing on the lifecycle management of established drugs, including reformulation and fixed-dose combinations. Additionally, global health initiatives aimed at tackling antimicrobial resistance are creating room for funding and partnerships, making the antifungal space an active area for clinical research. The growing emphasis on patient safety, combined with technological and therapeutic advancements, continues to shape a competitive and innovation-driven antifungal drug landscape.

Antifungal Drugs Market Report Highlights

By drug class, the azoles drug segment accounted for ~48% of the revenue share in 2024 due to their broad-spectrum activity and established clinical effectiveness in treating both superficial and systemic fungal infections.

Based on indication, the candidiasis segment held the largest revenue share in 2024 due to its high prevalence among immunocompromised and hospitalized patients.

In 2024, North America accounted for a ~41% share of the global antifungal drugs market revenue due to the strong presence of advanced healthcare infrastructure, frequent use of immunosuppressive therapies, and a growing elderly population.

The market in Asia Pacific is expected to register the highest CAGR during the forecast period due to rapid improvements in healthcare access and growing awareness of fungal infections.

A few global key players include Abbott; Astellas Pharma, Inc.; Bayer AG; Enzon Pharmaceuticals, Inc.; Glenmark; GSK plc; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; and Sanofi.

Polaris Market Research has segmented the antifungal drugs market report on the basis of drug class, indication, dosage form, distribution channel, and region:

By Drug Class Outlook (Revenue, USD Billion, 2020-2034)

Azoles

Echinocandins

Polyenes

Allylamines

Others

By Indication Outlook (Revenue, USD Billion, 2020-2034)

Dermatophytosis

Aspergillosis

Candidiasis

Others

By Dosage Form Outlook (Revenue, USD Billion, 2020-2034)

Oral Drugs

Ointments

Powders

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Antifungal Drugs Market Insights

  • 4.1. Antifungal Drugs Market - Market Snapshot
  • 4.2. Antifungal Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing Geriatric Population
      • 4.2.1.2. Rising Prevalence of Fungal Infections
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High costs of the products
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Antifungal Drugs Market Power Rating Trends
  • 4.6. Value Chain Analysis

5. Antifungal Drugs Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Antifungal Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 5.3. Azoles
    • 5.3.1. Antifungal Drugs Market, by Azoles, by Region, 2020-2034 (USD Billion)
  • 5.4. Echinocandins
    • 5.4.1. Antifungal Drugs Market, by Echinocandins, by Region, 2020-2034 (USD Billion)
  • 5.5. Polyenes
    • 5.5.1. Antifungal Drugs Market, by Polyenes, by Region, 2020-2034 (USD Billion)
  • 5.6. Allylamines
    • 5.6.1. Antifungal Drugs Market, by Allylamines, by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

6. Antifungal Drugs Market, by Indication

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
  • 6.3. Dermatophytosis
    • 6.3.1. Antifungal Drugs Market, by Dermatophytosis, by Region, 2020-2034 (USD Billion)
  • 6.4. Aspergillosis
    • 6.4.1. Antifungal Drugs Market, by Aspergillosis, by Region, 2020-2034 (USD Billion)
  • 6.5. Candidiasis
    • 6.5.1. Antifungal Drugs Market, by Candidiasis, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

7. Antifungal Drugs Market, by Dosage Form

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • 7.3. Oral Drugs
    • 7.3.1. Antifungal Drugs Market, by Oral Drugs, by Region, 2020-2034 (USD Billion)
  • 7.4. Ointments
    • 7.4.1. Antifungal Drugs Market, by Ointments, by Region, 2020-2034 (USD Billion)
  • 7.5. Powders
    • 7.5.1. Antifungal Drugs Market, by Powders, by Region, 2020-2034 (USD Billion)
  • 7.6. Others
    • 7.6.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

8. Antifungal Drugs Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.3. Hospital Pharmacies
    • 8.3.1. Antifungal Drugs Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 8.4. Retail Pharmacies
    • 8.4.1. Antifungal Drugs Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
  • 8.5. Others
    • 8.5.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)

9. Antifungal Drugs Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Antifungal Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 9.3. Antifungal Drugs Market - North America
    • 9.3.1. North America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
    • 9.3.2. North America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
    • 9.3.3. North America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.3.4. North America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.3.5. Antifungal Drugs Market - US
      • 9.3.5.1. US: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.3.5.2. US: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.3.5.3. US: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.3.5.4. US: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.3.6. Antifungal Drugs Market - Canada
      • 9.3.6.1. Canada: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.3.6.2. Canada: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.3.6.3. Canada: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.3.6.4. Canada: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • 9.4. Antifungal Drugs Market - Europe
    • 9.4.1. Europe: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
    • 9.4.2. Europe: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
    • 9.4.3. Europe: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.4.4. Europe: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.5. Antifungal Drugs Market - UK
      • 9.4.5.1. UK: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.5.2. UK: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.5.3. UK: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.5.4. UK: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.6. Antifungal Drugs Market - France
      • 9.4.6.1. France: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.6.2. France: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.6.3. France: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.6.4. France: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.7. Antifungal Drugs Market - Germany
      • 9.4.7.1. Germany: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.7.2. Germany: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.7.3. Germany: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.7.4. Germany: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.8. Antifungal Drugs Market - Italy
      • 9.4.8.1. Italy: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.8.2. Italy: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.8.3. Italy: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.8.4. Italy: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.9. Antifungal Drugs Market - Spain
      • 9.4.9.1. Spain: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.9.2. Spain: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.9.3. Spain: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.9.4. Spain: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.10. Antifungal Drugs Market - Netherlands
      • 9.4.10.1. Netherlands: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.10.2. Netherlands: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.10.3. Netherlands: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.10.4. Netherlands: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.11. Antifungal Drugs Market - Russia
      • 9.4.11.1. Russia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.11.2. Russia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.11.3. Russia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.11.4. Russia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.4.12. Antifungal Drugs Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.4.12.2. Rest of Europe: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.4.12.3. Rest of Europe: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.4.12.4. Rest of Europe: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • 9.5. Antifungal Drugs Market - Asia Pacific
    • 9.5.1. Asia Pacific: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
    • 9.5.2. Asia Pacific: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
    • 9.5.3. Asia Pacific: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.5.4. Asia Pacific: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.5. Antifungal Drugs Market - China
      • 9.5.5.1. China: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.5.2. China: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.5.3. China: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.5.4. China: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.6. Antifungal Drugs Market - India
      • 9.5.6.1. India: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.6.2. India: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.6.3. India: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.6.4. India: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.7. Antifungal Drugs Market - Malaysia
      • 9.5.7.1. Malaysia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.7.2. Malaysia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.7.3. Malaysia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.7.4. Malaysia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.8. Antifungal Drugs Market - Japan
      • 9.5.8.1. Japan: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.8.2. Japan: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.8.3. Japan: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.8.4. Japan: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.9. Antifungal Drugs Market - Indonesia
      • 9.5.9.1. Indonesia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.9.2. Indonesia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.9.3. Indonesia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.9.4. Indonesia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.10. Antifungal Drugs Market - South Korea
      • 9.5.10.1. South Korea: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.10.2. South Korea: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.10.3. South Korea: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.10.4. South Korea: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.11. Antifungal Drugs Market - Australia
      • 9.5.11.1. Australia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.11.2. Australia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.11.3. Australia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.11.4. Australia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.5.12. Antifungal Drugs Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.5.12.2. Rest of Asia Pacific: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.5.12.3. Rest of Asia Pacific: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.5.12.4. Rest of Asia Pacific: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • 9.6. Antifungal Drugs Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
    • 9.6.2. Middle East & Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
    • 9.6.3. Middle East & Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.6.4. Middle East & Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.6.5. Antifungal Drugs Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.6.6. Antifungal Drugs Market - UAE
      • 9.6.6.1. UAE: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.6.6.2. UAE: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.6.6.3. UAE: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.6.6.4. UAE: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.6.7. Antifungal Drugs Market - Israel
      • 9.6.7.1. Israel: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.6.7.2. Israel: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.6.7.3. Israel: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.6.7.4. Israel: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.6.8. Antifungal Drugs Market - South Africa
      • 9.6.8.1. South Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.6.8.2. South Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.6.8.3. South Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.6.8.4. South Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.6.9. Antifungal Drugs Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.6.9.2. Rest of Middle East & Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.6.9.3. Rest of Middle East & Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.6.9.4. Rest of Middle East & Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
  • 9.7. Antifungal Drugs Market - Latin America
    • 9.7.1. Latin America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
    • 9.7.2. Latin America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
    • 9.7.3. Latin America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 9.7.4. Latin America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.7.5. Antifungal Drugs Market - Mexico
      • 9.7.5.1. Mexico: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.7.5.2. Mexico: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.7.5.3. Mexico: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.7.5.4. Mexico: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.7.6. Antifungal Drugs Market - Brazil
      • 9.7.6.1. Brazil: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.7.6.2. Brazil: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.7.6.3. Brazil: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.7.6.4. Brazil: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.7.7. Antifungal Drugs Market - Argentina
      • 9.7.7.1. Argentina: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.7.7.2. Argentina: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.7.7.3. Argentina: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.7.7.4. Argentina: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
    • 9.7.8. Antifungal Drugs Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
      • 9.7.8.2. Rest of Latin America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
      • 9.7.8.3. Rest of Latin America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
      • 9.7.8.4. Rest of Latin America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbott
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Astellas Pharma, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Enzon Pharmaceuticals, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Glenmark
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. GSK plc
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Merck & Co., Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Novartis AG
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Pfizer, Inc
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Sanofi
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development